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Endometriosis affects millions of women in
the United States. It can severely alter qual-
ity of life and leads to extensive problems
with fertility and loss of work time. The
incidence of endometriosis in the U.S. popu-
lation is currently estimated at approxi-
mately 15% of reproductive-age women, but
this estimate is far from certain (1,2).
Signiﬁcant complicating issues are diagnosis
and ascertainment, as well as social and cul-
tural mores. It has been suggested (3) that
the incidence of endometriosis has increased
over the past 50 years. There also appears to
be a decrease in the age of onset, so whereas
endometriosis often was considered a disor-
der associated with delayed childbearing,
young teens are now being diagnosed with
this condition (4). The severity of the disease
is also hard to gauge, for although pain is a
usual companion of the condition, in the
most serious cases there is often no pain at
all. The degree of pain is not correlated with
the amount of ectopic material found.
Immune suppression has been associated
with severe endometriosis (5). In fact, the
recognition that endometriosis is not only a
reproductive and endocrine disorder but is
also associated with dysfunction of the
immune system has major implications not
only for understanding the pathogenesis of
this disorder but for potential therapies.
Endometriosis involves the inappropriate
and uncontrolled growth of endometrial
cells, normally conﬁned to the lining of the
uterus, outside the womb (4). Some scien-
tists consider endometriosis a benign neo-
plastic disorder. As in nonmalignant tumors,
cells have lost their normal control, often
dedifferentiate, and grow in an inappropriate
place. Although such a tumor is nonmetasta-
tic, it can still cause a great deal of pain and
suffering. Such is the case for endometriosis.
Growing in their appropriate environment,
endometrial cells are critical components of
the reproductive tissue and function of
women. However, when present outside the
uterus, endometrial cells lack the normal
growth control exerted by factors in their
normal environment, but continue to
respond to hormonal signals, causing non-
cyclical growth and regression of such tissue
wherever it may have attached—the peri-
toneal cavity, the intestines, on the ovary or
the outside of the uterus, the bladder, even
on the lungs and in the pleural cavity. 
Some of the most intriguing ﬁndings are
that endometriosis can even be found in
men who are highly exposed to antiandro-
gens and estrogens, such as in therapy for
prostate cancer (6). Clearly, these men never
had a uterus to produce the endometrial
cells. Rather, dedifferentiation and then red-
ifferentiation of other tissues has likely
occurred under the influence of antiandro-
gen and estrogen therapy. In women, the
major hypothesis for the origin of endome-
trial tissue outside of the uterus is retrograde
menstruation (7). That is, a certain amount
of endometrial cells escape from the uterus
to the peritoneal cavity via the Fallopian
tubes instead of exiting via the vagina during
menstruation. Koninckx (3) postulated that
either peritoneal leukocytes fail to remove
these retrograde endometrial cells or peri-
toneal leukocytes and retrograde endometrial
cells produce increased levels of cytokines
and growth factors that facilitate ectopic
endometrial growth. The endometrial cells
may then be able to attach to organs and/or
tissues on which they have landed. Once
attached, the endometrial cells may be able
to invade the underlying tissue, leading to
deep lesions. The endometrial lesions often
involve fluid-filled cysts, but they can also
have different architecture, especially if they
are highly invasive. Although the cysts are
readily detected on the surface of the
affected organ, the invasive lesions may be
entirely below the surface and not readily
detected, even by visual observation during
surgery. Nevertheless, the clinical standard for
diagnosing endometriosis involves surgery;
without it, endometriosis is often missed.
However, many efforts have been made to
improve the detection of endometriosis via
nonsurgical means, including careful patient
history, medical examination, magnetic reso-
nance imaging, and ultrasound methods (4).
Endometriosis requires estrogen (8,9).
Growth of the endometrial cells, whether in
the uterus or outside it, depends on estrogen.
This dependency is the basis for the major
therapeutic approach to endometriosis treat-
ment with androgens or antiestrogens.
Hysterectomy and ovariectomy is a treat-
ment, but one of last resort. Even this may
not solve the problem because the extrauter-
ine implants can still respond to the estro-
gens that are produced by the adrenal glands
and by peripheral tissues from adrenal-
derived androgens. Recent data suggest that
endometrial cysts have developed the ability
to produce their own estrogens in situ from
circulating androgens produced by the adren-
als. Noble et al. (10) have shown that human
endometrial explants have high levels of aro-
matase, the enzyme that converts testos-
terone to estrogen. Thus, in endometriosis,
the lesions have achieved independence from
the circulating levels of estrogens. Under this
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A potential connection exists between exposure to organochlorine chemicals and the increasing
prevalence of endometriosis. Evidence shows that dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin)
can increase the incidence and severity of the disease in monkeys and can promote the growth or
survival of endometrial tissue implanted into rodents in a surgically induced model of
endometriosis. The mechanism of the connection between organochlorine chemicals and
endometriosis is not clear. Effects on growth factors, cytokines, and hormones (components of
the immune and endocrine systems) are potential means of mediating the possible promotion of
endometriosis by dioxins. Studies on epidemiology and on structure–activity relationships of
organochlorine chemicals and endometriosis have been additional approaches to this problem. In
this regard, toxic equivalence (TEQ) appears to be an important determinant of the effects of
organochlorine chemicals on endometriosis. In this article, we review the literature related to
endometriosis and dioxins and attempt to integrate the various sources of information that bol-
ster the hypothesis connecting dioxins and endometriosis. Key words: dioxin, endometriosis, poly-
chlorinated biphenyls, TCDD, toxic equivalence. Environ Health Perspect 110:15–21 (2002).
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clearly not have the desired effect. In
contrast, antiestrogens may still be effective
if they can reach the site of the lesions. But
not all endometrial lesions are highly vascu-
larized, making serum therapies sometimes
ineffective.
As mentioned above, some of the increase
in reported incidence of endometriosis may
derive from better ascertainment and report-
ing. However, other possibilities include
higher estrogen levels in women caused by
diet and medicines. One major recent
hypothesis deserving attention is that envi-
ronmental agents may play a role in the
increased incidence of endometriosis. This
hypothesis was ﬁrst advanced for a nonchem-
ical stressor, radiation. Studies in nonhuman
primates, specifically rhesus monkeys,
revealed that a single radiation treatment led
to an increase in endometriosis in the colony
after a latency of 7 years (11). To date, how-
ever, there have been no human studies to
either support or refute this hypothesis.
As mentioned above, estrogen is required
for endometriosis. Removal of estrogen (e.g.,
by ovariectomy) tends to reduce symptoms.
In contrast, estrogen therapy restores and/or
exacerbates the problem. Rodent models
have been developed to examine the role of
environmental estrogens in endometriosis.
Because of a variety of differences in
anatomy and physiology between the rodent
and the primate, rodents do not develop
endometriosis spontaneously. However,
endometrial tissue from the same or geneti-
cally matched rodent can be surgically
implanted in the peritoneum or mesentery
of a recipient rat or mouse, and estrogen can
then promote the growth of these implants.
This approach was initially developed in rats
by Vernon et al. (12) and used to develop
antiendometriotic therapies. However,
Cummings and Metcalf (13) extended the
model to involve surgical induction of
endometriosis in the mouse. They demon-
strated that the implants required estrogen
for growth. For example, although the
implants had a mean diameter of 3.60 mm in
the intact mouse, ovariectomy reduced the
size of the lesions to 0.95 mm. Treatment
with estrogen increased the lesion size to
5.28 mm, significantly greater than in the
absence of endogenous estrogens. Using the
rat model, they also showed that the envi-
ronmental pesticide methoxychlor, which
can be metabolized to a chemical with high
affinity for the estrogen receptor, had the
same ability as estrogen to promote the
growth of the endometrial implant (14).
Methoxychlor is an example of a syn-
thetic organochlorine. Organochlorines con-
stitute a large and complex group of
synthetic organic compounds that contain
chlorine atoms. The presence of chlorine
tends to make the chemicals more stable,
both to environmental insult and to biologic
breakdown. In fact, certain organochlorines
are extremely persistent and bioaccumula-
tive. These include pesticides such as DDT,
mirex, and toxaphene, industrial chemicals
such as polychlorinated biphenyls and pen-
tachlorphenol, and unwanted byproducts,
primarily of industrial processes, such as
polychlorinated dibenzo-p-dioxins and
dibenzofurans. These chemicals are of con-
cern internationally and are the subject of
international negotiations leading toward a
regulatory treaty.
One of the compounds of greatest con-
cern is TCDD (2,3,7,8-tetrachlorodibenzo-
p-dioxin; dioxin). TCDD is an unwanted
byproduct of many industrial and combus-
tion processes (15). It is a prototype for a
family of chemicals that have a common
mechanism of action and a common
spectrum of effects, are structurally related,
and are persistent and bioaccumulative.
Members of this group are often called the
polyhalogenated aromatic hydrocarbons
(PHAHs). They may contain multiple chlo-
rine and/or bromine atoms, at three or more
lateral positions on the multiaromatic ring
structure. Well-characterized families
include the polyhalogenated dibenzo-p-
dioxins (PCDDs and PBDDs), dibenzofu-
rans (PCDFs and PBDFs), biphenyls
(PCBs/PBBs), naphthalenes (PCNs/PBNs),
and azo-azoxybenzenes, among others.
Certain PCBs are dioxin-like in their effects.
In fact, PCBs are never present without
dioxin-like PCBs. The toxicity of members
of these classes can be assessed using a toxic
equivalency factor (TEF) approach in which
all chemicals that are dioxin-like are assigned
a relative potency factor that expresses their
toxicity in relation to that of TCDD
(16,17). The TEF values are consensus esti-
mates based on an evaluation of all the avail-
able data. The total toxic equivalency (TEQ)
is the sum of the mass of each individual
congener times its individual TEF:
[(PCDD1) × TEF1] + [(PCDD2) × TEF2] ...
[(PCDDx)] × TEFx].
More is known about the mechanism of
toxicity of TCDD than of almost any other
chemical. The ﬁrst step in its action involves
binding to the Ah receptor, which functions
as a ligand-activated transcription factor
(18). In addition, recent studies suggest that
the Ah receptor may act as a competitor for
the PAS (Per-ARNT-SIM) family of nuclear
regulatory proteins, which includes ARNT, a
protein that controls hypoxic stress and circa-
dian rhythms, and SIM, which plays a key
role in neurodevelopment. The unliganded
form of the Ah receptor also appears to be a
negative regulator of tyrosine phosphorylation
(e.g., c-src), apoptosis (e.g., rel), and cell
cycling (e.g., Rb) (19). One of the key points
about dioxins is that effects of the chemicals
are seen in both sexes of multiple strains of a
broad spectrum of laboratory animals, domes-
tic animals, wildlife, and humans (15,18).
The effects of dioxin and related com-
pounds range from the molecular and bio-
chemical, through the cellular, to the tissue,
organ, and systems level (15,20,21).
Biochemical effects include induction of
enzymes involved in metabolism of both
endogenous substances as well as xenobi-
otics, oxidative stress, and induction of spe-
ciﬁc cytokines. At the cellular level, dioxins
can induce either proliferation or differentia-
tion, depending on the state and environ-
ment of the cells. The key role of the cellular
environment is also seen in that apoptosis
has been reported to be both induced or
blocked by dioxins (22). Dioxins also per-
turb homeostasis at the systemic level.
Dioxin is a known human carcinogen
(23,24) and is toxic to multiple organ sys-
tems. Dioxins are reproductive and develop-
mental toxicants, as well as being neurotoxic
and immunotoxic (22,25). Dioxin is the
prototypical endocrine disruptor, modulat-
ing essentially every hormone system investi-
gated: at the level of the receptor, by altering
metabolism, or by affecting serum transport.
These hormonal effects involve both the
steroid family (e.g., estrogen, androgen, thy-
roid, glucocorticoid) and peptide (e.g., pro-
lactin, insulin) hormones and are tissue- and
developmental-stage-speciﬁc. Dioxins induce
multiple enzymes, and dioxins can lead to
the generation of reactive oxygen species,
leading to oxidative stress (26). Growth fac-
tors control proliferation, differentiation,
and apoptosis. Dioxin effects on growth fac-
tors and their receptors have been seen on
retinoic acid and its receptors, tumor growth
factor α and β, the epidermal growth factor
receptor, and the insulin growth factor recep-
tor. Cytokines such as tumor necrosis factor
and interleukins (IL) 1β and 6 have also been
shown to be induced by dioxin exposure
(27,28). Cytokines are key signaling molecules
in the immune and nervous systems. TCDD
has been shown to be an immune suppressant
in multiple systems and was also recently sug-
gested to cause autoimmunity in a mouse
model (29). TCDD suppresses T-cell–medi-
ated B-cell responses. It also causes a block in
T-cell maturation and is associated with
thymic atrophy at high doses in all species
investigated. Dioxins cause an increase in IL-
1β and tumor necrosis factor β1, and the
region of DNA that recognizes the ligand-acti-
vated Ah receptor, the dioxin response ele-
ment, is present in IL-1β, IL-2, IL-5, IL-6,
IL-10, tumor growth factor β1, and interferon
γ (27,28).
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dioxin, the most toxic of the organochlorines,
is associated with the observed increase in
endometriosis in the developed world. The
association of endometriosis with organochlo-
rines, speciﬁcally PCBs that are not dioxin-
like, was ﬁrst reported from Germany (30). A
letter from Belgian epidemiologists (31) sug-
gested that the higher prevalence of endo-
metriosis at infertility clinics in Belgium
could be caused by the relatively high
TCDD concentration in the Belgian popula-
tion. These epidemiologic findings were
essentially coincident with the publication of
a study (32) demonstrating an increase in
both the incidence and severity of sponta-
neous endometriosis in a colony of rhesus
monkeys that had been exposed to TCDD
in their diet for 4 years and then held for up
to 10 years longer. These were incidental
ﬁndings; the TCDD treatment of the mon-
keys had occurred many years previously.
The monkeys had been held because of their
potential value for long-term effects of expo-
sure to dioxin. The hypothesis that TCDD
exposure was associated with endometriosis
arose when three of the high-dose monkeys
(out of seven) died from fulminating
endometriosis, the ﬁrst one 7 years after cessa-
tion of the 25-ppt TCDD diet. Laparoscopic
observations were conducted on all surviving
monkeys from this dose group, as well as the
lower-dose (5 ppt) group and the controls
10 years after diet cessation. Whereas 33% of
the dietary control animals had endometrio-
sis, 70% of those receiving the low dose and
more than 80% of the high-dose animals had
either died of endometriosis or had been sur-
gically diagnosed. The increased incidence
was statistically significant at both dietary
levels. In addition, the severity of the disease
demonstrated a dose-related increase.
Endometriosis in the two control monkeys
(of six surviving monkeys at the time exam-
ined) was stage I according to the standard
American Fertility Scale, as used to classify
endometriosis in women. In the 5-ppt
group, out of seven surviving monkeys, ﬁve
with endometriosis, two were stage I, two
were stage III, and one was the most severe,
stage IV. Only one monkey in the high-dose
(25 ppt TCDD in diet) group was free of
endometriosis at this 10-year postexposure
analysis. Of the six high-dose monkeys with
endometriosis, none were stage I, one was
stage II, one was stage III, and four had the
most severe form of endometriosis, stage IV.
Rier and co-workers (32) concluded that
TCDD exposure was associated with an
increase in both the incidence and severity of
endometriosis in rhesus monkeys. 
The publication of these experimental
ﬁndings, along with the suggestive epidemi-
ologic associations, led to additional animal
research to test this hypothesis. Several
groups of investigators used rodent models
to explore this question. Bruner and co-
workers (33) developed a hybrid model
involving human endometrium implanted in
nude mice. Cells from uterine endometrium
were exposed in vitro to estrogen, estrogen
and progesterone, estrogen plus TCDD, or
estrogen and progesterone plus TCDD. The
cultured cells were then injected into
ovariectomized nude mice treated continu-
ously with estrogen, and the numbers of
endometrial lesions in the mouse peri-
toneum were counted after 10–12 days.
Progesterone is well known to inhibit the
growth of endometrial tissue, and while 20
lesions in eight mice were seen from the
injected cells cultured with estrogen alone,
these were totally blocked by the co-culture
with progesterone. In contrast, TCDD more
than doubled the number of estrogen-
induced lesions to 42 in eight mice. This
effect of dioxin could not be blocked by
progesterone; in fact, 48 lesions were
observed in co-treated mice.
Surgical induction of endometriosis by
implantation of endometrial tissue into the
mesentery was used to demonstrate the key
role of estrogen and the ability of antiestro-
gens to block endometrial growth and has
been used to test the promotion of endome-
trial growth by TCDD in both rats and
mice. Cummings et al. (34) developed a pro-
tocol to be used in both species of rodents
(see Figure 1) which involved five repeated
doses of TCDD over 12 weeks, with the
rodents held for 15 weeks. The surgical
induction of endometriosis occurred 3 weeks
after the ﬁrst dose of dioxin. Repeated doses
of 0, 3, or 10 µg/kg TCDD were given to
B6C3F1 mice or Sprague-Dawley rats.
Rodents were killed 3, 6, 9, and 12 weeks
after the endometrial implantation surgery,
and the implants were measured. No signiﬁ-
cant increase in endometriosis could be
detected in rats until 12 weeks after the
surgery, which also involved ﬁve doses of 10
µg TCDD/kg per dose, for a total dose of 50
µg/kg. If all the treatment groups were
pooled across time and within dose, the
induction of endometriosis was signiﬁcant at
the 10 µg/kg dose of TCDD. In contrast,
the induction of endometriosis in mice
could be detected by 9 weeks after the
surgery at both doses, 3 and 10 µg/kg,
involving total doses of 12 and 40 µg/kg.
This dioxin-induced promotion of surgical
endometriosis was still detectable 12 weeks
after surgery. 
These studies demonstrated that the pro-
motion of surgically induced endometriosis
was both dose and time related. Yang and
Foster (35) ovariectomized mice, implanted
them with estrogen-containing pellets
designed to supply a constant stream of
estrogen into the blood, and surgically
implanted endometrial tissues into the peri-
toneum. The mice were then exposed to up
to 100 ng TCDD/kg body weight for 28
days. At the end of that time, the diameter
of the implants was measured. Endometrial
implants from the high-dose animals were
signiﬁcantly smaller than those in controls. 
These data suggest that exposure to
TCDD does not promote the growth of
endometriotic lesions in mice. However,
there are problems rendering this interpreta-
tion in doubt. The ﬁrst is that Cummings et
al. (34) demonstrated that there is a time
requirement to see the dioxin-induced pro-
motion of endometrial growth. At least 9
weeks are required for the difference in size
of TCDD-treated versus control lesions to
be observed. Yang and Foster (35) allowed
only 4 weeks for this process to occur. In
addition, it is likely that the exposure of ani-
mals to TCDD before surgery, as in
Cummings et al.’s study, may predispose the
ectopic sites to be receptive to endometriotic
implantation. A recent report from Japan
also showed not a promotion of the growth
of implanted endometrial tissue by TCDD
but a regression of the implants (36). Again,
this group failed to allow sufﬁcient time for
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Figure 1. Protocol for the evaluation of the effect of 2,3,7,8-TCDD on surgically induced endometriosis in
rodents. Animals were dosed 3 weeks before the induction surgery, again on the day of surgery, and
three more times at 3-week intervals ending on the 9th week after surgery. Groups of animals were killed
at 3-week intervals beginning 3 weeks after surgery and ending 12 weeks after surgery at which time
evaluations included the size and/or weight of the induced endometriotic lesions. [Based on Yang and
Foster (35).] the growth differential to be observed. It
should be noted that Matsui et al. (36) used
Ah receptor knock-out mice. The study can
thus be considered to have examined the role
of the Ah receptor in endometriosis, and it is
apparent that the Ah receptor is required for
the promotion of endometriosis by TCDD. 
Another problem is that the ovariectomy
of the animals plus treatment with estrogen
confounds the physiologic basis of the
model. A comparison of the ovariectomized
model with the intact rodent model of
TCDD-promoted surgically induced
endometriosis suggests that ovarian factors
are involved that are not yet defined. The
presence of the ovary may be necessary for
the secretion of hormones or factors that
might affect the availability of Ah receptors
or that otherwise might affect the immuno-
competency of the animals or the growth of
endometriotic tissue independent of TCDD.
The model of TCDD-promoted surgically
induced rodent endometriosis in which the
ovaries are removed (35) differs from the
ovariectomized nude mouse model of
endometriosis (33) in that human endome-
trial or endometriotic tissue is used for the
implants in the latter, whereas rodent
endometrial tissue is autotransplanted in the
former. The two ovariectomized rodent
models are limited by the absence of the
influence of the ovary, which supplies a
complex physiologic milieu that may be
required for the response. The intact model
is somewhat limited by the hormonal effects
of the rodent estrous cycles, which can com-
plicate the collection of data on endometriotic
lesions due to the effects of the hormones on
the size of the lesions.
Thus, the promotion of endometriosis in
rodents by TCDD is both dose and time
related, increases the size of the implants,
requires estrogen, and is not blocked by prog-
esterone. The mechanism of this response
appears to involve the Ah receptor, the spe-
cific basic helix-loop–helix PAS protein
required for essentially all of the activities of
TCDD. Evidence for the role of the Ah
receptor usually comes from studies demon-
strating structure–activity relationships
and/or genetics (18). To date, only the ﬁrst
category of studies have been conducted.
Johnson and co-workers (37) used surgically
implanted endometrial lesions in mice
according to the model of Cummings et al.
(34). Mice were exposed once before and
four times after surgery, at 3-week intervals,
to TCDD or four other polyhalogenated
aromatic hydrocarbons, two of which are
high-affinity agonists for the Ah receptor,
2,3,4,7,8-pentachlorodibenzofuran
(4PeCDF) and 3,3´,4,4´,5-pentachloro-
biphenyl (PCB 126); and two of which do
not bind, 2,2´,4,4´,5,5´-hexachlorobiphenyl
(PCB 153) and 1,3,6,8,-tetrachlorodibenzo-
p-dioxin (1,3,6,8-TCDD). Doses were
selected on the basis of the relative potency
of these congeners to TCDD. The study by
Johnson et al. (37), which predated the
World Health Organization publication of
relative TEF values, used enzyme data
obtained in Birnbaum’s laboratory to deter-
mine relative potency. TCDD, 4PeCDF,
and PCB 126 all promoted the growth of
the endometrial implants (Figure 2). In con-
trast, the non-Ah receptor ligands PCB 153
and 1,3,6,8-TCDD failed to alter the
growth properties as compared to controls.
Although not definitive, these results sup-
port the role of the AhR in endometriosis.
The mouse model has also been used to
address the issue of whether exposure early
in life can alter the susceptibility of the adult
to dioxin-promoted endometriosis. Both rats
and mice were exposed on gestation day 8 to
doses of 1, 3, or 10 µg TCDD/kg (38). At 9
weeks of age, the prenatally exposed pups
were treated with 1, 3, or 10 µg TCDD/kg,
held for 3 weeks, and then had endometrial
tissue surgically implanted according to
Cummings et al. (34). This was followed by
four additional doses of TCDD at 3-week
intervals. Although no enhanced sensitivity
to endometriosis could be detected in the
rat, which appears less susceptible to this
response overall than the mouse—possibly
because of the decreased sensitivity of the
adult immune system of the rat to dioxin-
induced immune suppression—prenatal
exposure to a low dose of TCDD resulted in
greater sensitivity of the mouse pup to surgi-
cally induced endometriosis as an adult (38).
This ability of TCDD to induce delayed
developmental effects on endometriosis is in
line with other reports demonstrating that
prenatal exposure to dioxins is associated
with altered breast and vaginal development
in female pups, decreased sperm counts and
altered seminal vesicle and prostate mor-
phology in male offspring, deﬁcits in learn-
ing and memory and behavioral alterations,
permanent immune suppression, and
decreases in core body temperature (39–47).
Several other investigations have fol-
lowed up on the initial association with
endometriosis and TCDD in rhesus mon-
keys (32). A preliminary report had appeared
earlier from a Canadian study with rhesus
monkeys exposed to PCBs (48). Early deaths
were associated with endometriosis in mon-
keys exposed to a high dose of Aroclor 1254.
(Aroclor 1254 is a commercial mixture of
PCBs which is 54% chlorine by weight.)
However, following the Rier et al. (32)
study, Arnold and co-workers (49) con-
ducted a thorough review of the pathology
reports from the PCB monkey study and
reported no significant association between
exposure to this complex mixture of PCBs
and endometriosis (49). There are several
potential explanations for the apparent dis-
crepancy between the Canadian results and
those of Rier et al. The most obvious one is
that the monkeys in the Canadian study
were exposed to PCBs, not to TCDD.
Although there are some dioxin-like PCBs in
Aroclor 1254, most of the PCBs have no
dioxin-like activity. Therefore, in agreement
with the studies of Johnson et al. (37), one
would not expect endometriosis in this
cohort. Another explanation may be that the
Canadian monkeys were not held long
enough for the endometriosis to become
apparent. Studies with radiation demon-
strated that at least 7 years were required for
endometriosis to appear. In the Rier cohort,
endometriosis was not detected until at least
11 years after the initiation of exposure to
TCDD (7 years after the feeding stopped).
The total time of the PCB exposure and
postexposure part of the study was only 6
years, possibly inadequate for appearance of
endometriosis in the monkeys.
In contrast, Rier has followed up on
analysis of the original cohort of rhesus
monkeys exposed to TCDD for 4 years in
their diet. After a total of 17 years from the
onset of exposure, endometriosis was
assessed in all of the monkeys (50). There
was a clear association between TCDD
exposure and endometriosis. However, in
addition, Rier et al. (50) observed an associa-
tion between endometriosis and TEQ, in
many cases determined not entirely by the
historical TCDD dietary exposure, but also
by PCBs, especially 3,3´,4,4´-tetrachloro-
biphenyl (PCB 77), PCB 126, as well as
4PeCDF in serum. The source of these
PCBs in the monkeys has not been deter-
mined, but the presence of PCBs was also
observed in another cohort of monkeys
maintained in the same facility which had
been exposed to lead (50). In these lead-
(and, apparently, PCB-) exposed monkeys,
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Figure 2. A comparison of the effect of selected
polyhalogenated aromatic hydrocarbons on the
growth of surgically induced endometriotic
lesions in rats. The method used for treatment of
the animals was identical to that depicted in
Figure 1. Data represent the mean and SE. [Data
from Cummings et al. (38).] there was also an association between TEQ
and endometriosis that is a function of the
dioxin-like PCB levels and not the lead.
This suggests that it is the activation of the
Ah receptor by both dioxins and other Ah
receptor ligands that is associated with
endometriosis.
Recently, Yang et al. (51) demonstrated
that surgically induced endometriosis in
cynomolgus monkeys could be promoted by
TCDD. After the implantation of endome-
trial tissue in the peritoneum, the monkeys
were treated with TCDD 5 days per week for
1 year, at which time the survival and size of
the implants were measured. There was a
dose-related increase in the percentage of sur-
viving implants (Figure 3). This increase in
survival was significant at both the middle
(3.57) and high doses (17.86 ng/kg/day).
There was also a significant decrease in the
size of the implants at the lowest dose (0.71
ng/kg/day) compared to the control monkeys.
However, the size of the implants was signiﬁ-
cantly larger than in the controls at the high
dose. An interesting aspect of these studies is
the examination of the cytokine signaling
pathway involving IL-6, a key mediator in the
immune system. Yang et al. (51) observed a
dose-related decrease in the circulating levels
of IL-6 after 6 months of TCDD treatment.
However, after 1 year, the decrease was only
evident in the high-dose group. These results
were compatible with analysis of the levels of
IL-6 receptor, which is normally regulated in
a negative feedback loop with its ligand, Il-6.
Yang et al. (51) observed a dose-related
increase in the concentration of IL-6 receptor
at 6 months, but there was an increase only in
the high-dose group after 1 year.
Nevertheless, these studies clearly indicate
that TCDD has affected the immune system
of these monkeys, which may play a role in
the enhanced survival of the endometrial
implants.
Thus, to date the weight of the evidence
seems to support an association between
TCDD and related chemicals and endo-
metriosis in experimental animals. TCDD
and TEQ are associated with both sponta-
neous and surgically induced endometriosis
in two species of nonhuman primates.
TCDD and TEQ promote the growth of
surgically induced endometriosis in both rats
and mice. And prenatal exposure to TCDD
may increase the sensitivity to endometriosis
during adulthood. 
The situation in humans is less clear. The
ecologic epidemiology reports in the early
1990s of an association between organochlo-
rines and endometriosis gained prominence
with the publication of Rier et al.’s (32)
monkey study. This led to a cohort study in
Israel in which the plasma concentrations of
TCDD were compared in 44 women with
surgically confirmed endometriosis to 35
women with no surgical evidence of this con-
dition (52). The women were matched for
socioeconomic status and age but not ethnic
backgrounds. The percentage of women with
dioxin above the limits of detection in this
study (2 ppt) increased with the incidence of
endometriosis. Only 1 of 35 women without
any endometriosis had dioxin > 2 ppt. In
contrast, 3 of 24 women with stage I and II
endometriosis had detectable dioxin, and
25% of the women with moderate and severe
endometriosis (stages III and IV) had con-
centrations of TCDD > 2 ppt. This study
supports the hypothesis, but the high limits
of analytic detection of TCDD and the fail-
ure to measure all of the TEQ introduce
some questions into the interpretation of this
study. However, it does encourage further
investigation.
Pauwels et al. (53) conducted a small
study in Belgium in which the total TEQ
was measured in plasma samples. Again, as in
the study by Mayani et al. (52), the presence
or absence of endometriosis was surgically
confirmed. In a report that did not present
the endometriosis data per se but presented
statistical evaluations, Pauwels et al. found a
high relative risk for endometriosis in associa-
tion with elevated TEQ, based on a bioassay
for all of the dioxin-like activity (PCDDs,
PCDFs, and dioxin-like PCBs). However,
because the number of women in these stud-
ies is small, the increased risk is not statisti-
cally signiﬁcant at the p = 0.05 level. There
was no association with total PCB measure-
ments, and this is in agreement with the ani-
mal data. Significantly, in both of these
studies, the blood levels are within the range
of the background population.
In contrast to these studies suggesting an
association between dioxins and endometrio-
sis, two other reports do not. Boyd et al.
(54) presented a preliminary report on 30
women, 15 with apparent endometriosis,
based on symptomology, and 15 with no
evidence of this condition. There was no
surgical ascertainment. These investigators
failed to observe any association between the
clinical diagnosis of endometriosis and the
dioxin equivalency due to polychlorinated
dibenzo-p-dioxins and dibenzofurans. They
did not measure the dioxin-like PCBs; there-
fore, they could not examine an association
with the total TEQ, as done by Pauwels et
al. (53). The lack of surgical ascertainment
of endometriosis is also an issue because
some of the controls may in fact have had
the condition, and some of those identiﬁed
as having endometriosis may have had other
diseases.
Another study failed to demonstrate an
association between total PCBs and
endometriosis. Lebel et al. (55) examined a
cohort of women in Quebec who were surgi-
cally diagnosed. The authors measured 14 of
the most common PCBs, but they did not
measure any of the dioxin-like PCBs, the
PCDDS, or PCDFs. Given the animal data,
as well as the other epidemiology studies, the
lack of an association with total PCBs is not
a surprise. Thus, to date, the data are not
deﬁnitive, but are suggestive because the few
negative studies are confounded by disease
ascertainment and by comparison to the
wrong metric (i.e., to PCBs and not to
TEQ). A study is being conducted involving
women in Seveso, the Italian town poisoned
by dioxin in 1976 (56). Women in the two
most highly contaminated zones are being
examined for clinical diagnosis of endometri-
oisis. Blood levels of dioxin from samples
taken shortly after the incident are being
measured. However, surgical evaluation is
not being conducted, leading to the possibil-
ity of misclassiﬁcation of disease status. Also,
the total TEQ is not being determined, and
although this was primarily a TCDD poison-
ing, the levels of other dioxins may con-
tribute to the risk as well. A meta-analysis
involving surgical diagnosis of disease status
as well as measurement of total TEQ might
allow greater confidence in confirming or
refuting the association between endometrio-
sis and dioxins. To date, none of these stud-
ies has detected clear differences in exposure
to dioxins between women with and without
endometriosis.
The etiology of endometriosis is often
thought to involve hormonal alterations as
well as changes in the immune system. Recent
studies aimed at developing a mechanistic
understanding of how dioxins could promote
endometriosis have focused on the effects of
dioxins on the endocrine and immune sys-
tems. Dioxin is the prototypical endocrine
disruptor (15), leading to alterations in every
hormone system investigated to date, both of
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Figure 3. Promotion by 2,3,7,8-TCDD on the sur-
vival rate of surgically induced endometriotic
implants in monkeys. Animals were treated with
TCDD for 1 year after the implantation of endome-
trial tissue in the peritoneum, and an evaluation of
the size and survival rate of the implants was
made. Data from Yang et al. (51).
*p < 0.05.the steroid family and peptide. Dioxins have
been shown in a cell, tissue, developmental
stage, and species-speciﬁc manner to modulate
hormone signaling via changes in the number
of receptors (up- vs. down-regulation), alter-
ation of the metabolism of the hormones
(increased/decreased synthesis/degradation),
and alteration of serum transport via
competition for plasma-binding proteins.
Endometriosis requires estrogen, both in clini-
cal situations and in experimental animal
models. However, even ovariectomy does not
always block the growth of endometrial
lesions. Bulun et al. (57) have demonstrated
that testosterone can be converted in situ in
endometrial implants to estrogen via aro-
matase action. The adrenal glands produce
androstenedione, which is converted by aro-
matase in peripheral tissues to estrone, and
which can be further metabolized to estradiol,
the most active form of estrogen, by 17β-
hydroxysteroid dehydrogenase. Thus, the
adrenal production of androgens can lead to
local elevation of estrogen. Also potentially sig-
niﬁcant about these ﬁndings is that aromatase
activity is enhanced by prostaglandins whose
production is increased when inﬂammatory
cytokines such as IL-1β and tumor necrosis
factor α are produced during an immune reac-
tion. In several animal models, TCDD
induced the synthesis of these cytokines
(58,59).
Another key requirement for the ability of
dioxin to promote the growth of endometrio-
sis is the presence of the required signaling
pathway for dioxin’s effects. Essentially all of
the effects of dioxin require binding to the Ah
receptor. Several laboratories have demon-
strated the presence of the Ah receptor in uter-
ine endometrium. Recently, Igarashi et al. (60)
demonstrated the presence of mRNAs, not
only for the Ah receptor but for its cognate
dimerization partner, ARNT, as well as genes
that are under the direct transcriptional con-
trol of the Ah receptor/ARNT heterodimer,
CYP1B1. These investigators showed that
these genes were expressed not only in normal
endometrium but in endometriosis as well,
demonstrating the ability of the diseased tissue
to respond to dioxins. However, Bulun et al.
(61) could ﬁnd no evidence that the presence
of endometriosis significantly altered the
expression of the Ah receptor or ARNT,
although another dioxin-responsive gene,
CYP1A1, was induced in endometriotic tis-
sues. Induction of CYP1A1 is often consid-
ered a biomarker for dioxin responsiveness.
These data are consistent with the data of
Bruner et al. (33), which suggest a direct effect
of TCDD on endometrial tissue independent
of other potential mechanisms such as those
affecting the immune or endocrine systems.
Thus, TCDD and related compounds,
well known to alter proliferation and
differentiation in multiple cells and tissues,
as well as to modulate hormones and the
immune system, clearly have the potential to
be associated with endometriosis. Dioxin is
also a known human carcinogen (23).
Recent studies have suggested that
endometriosis may be a type of benign neo-
plasm and that women with endometriosis
may be at elevated risk for cancer as well
(62). Animal studies, both in nonhuman pri-
mates and rodents, have shown that expo-
sure to dioxins can promote the growth of
spontaneous as well as surgically induced
endometriosis. Dioxin-like PCBs, but not
nondioxin-like PCBs, are associated with
endometriosis. Therefore, studies should look
at the association between the total TEQ, not
the total PCBs, and this disease. Surgical
ascertainment of endometriosis appears
essential to avoid misdiagnosis. Clear evi-
dence of a role for dioxins in the increased
incidence of endometriosis will require care-
ful cohort studies of women with and with-
out endometriosis coupled with adequate
exposure determination. If such an associa-
tion is confirmed, we speculate that the
decrease in exposure to dioxins that has been
occurring over the past 10–20 years might
eventually reverse the increase of this debili-
tating condition.
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